Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
TGFBR2 and GOPC transforming growth factor, beta receptor II (70/80kDa) golgi-associated PDZ and coiled-coil motif containing
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Glycerol
TGFBR2 and STRAP transforming growth factor, beta receptor II (70/80kDa) serine/threonine kinase receptor associated protein
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • Glycerol
TGFBR2 and ARHGEF7 transforming growth factor, beta receptor II (70/80kDa) Rho guanine nucleotide exchange factor (GEF) 7
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • EGFR downregulation
  • Signaling by GPCR
  • Signalling by NGF
  • Axon guidance
  • Cell death signalling via NRAGE, NRIF and NADE
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • p75 NTR receptor-mediated signalling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFRvIII in Cancer
  • Rho GTPase cycle
  • Signaling by EGFR
  • GPCR downstream signaling
  • Ephrin signaling
  • NRAGE signals death through JNK
  • Signaling by Rho GTPases
  • Signaling by EGFR in Cancer
  • EPH-Ephrin signaling
  • G alpha (12/13) signalling events
  • Glycerol
A1BG and CDKN1A alpha-1-B glycoprotein cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
A2M and CDKN1A alpha-2-macroglobulin cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Lipoprotein metabolism
  • Metabolism of lipids and lipoproteins
  • Platelet degranulation
  • Lipid digestion, mobilization, and transport
  • Degradation of the extracellular matrix
  • Formation of Fibrin Clot (Clotting Cascade)
  • Rho GTPase cycle
  • Intrinsic Pathway
  • HDL-mediated lipid transport
  • Response to elevated platelet cytosolic Ca2+
  • Signaling by Rho GTPases
  • Platelet activation, signaling and aggregation
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
  • Becaplermin
  • Bacitracin
  • Ocriplasmin
ACACA and BRCA1 acetyl-CoA carboxylase alpha breast cancer 1, early onset
  • Metabolism of vitamins and cofactors
  • Defective CD320 causes methylmalonic aciduria
  • Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF
  • Integration of energy metabolism
  • Metabolism of lipids and lipoproteins
  • ChREBP activates metabolic gene expression
  • Defective BTD causes biotidinase deficiency
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC
  • Defective MTR causes methylmalonic aciduria and homocystinuria type cblG
  • Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Fatty Acyl-CoA Biosynthesis
  • Defective AMN causes hereditary megaloblastic anemia 1
  • Triglyceride Biosynthesis
  • Defects in cobalamin (B12) metabolism
  • Defective GIF causes intrinsic factor deficiency
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective HLCS causes multiple carboxylase deficiency
  • Defective MMAB causes methylmalonic aciduria type cblB
  • Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD
  • Defective MMAA causes methylmalonic aciduria type cblA
  • Defective CUBN causes hereditary megaloblastic anemia 1
  • Metabolism of water-soluble vitamins and cofactors
  • Defective MUT causes methylmalonic aciduria mut type
  • Defects in biotin (Btn) metabolism
  • Activation of gene expression by SREBF (SREBP)
  • Defective TCN2 causes hereditary megaloblastic anemia
  • Biotin transport and metabolism
  • Defects in vitamin and cofactor metabolism
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Biotin
ACTB and CDKN1A actin, beta cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Axon guidance
  • Gap junction degradation
  • Adherens junctions interactions
  • Translocation of GLUT4 to the plasma membrane
  • L1CAM interactions
  • Recycling pathway of L1
  • HATs acetylate histones
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Interaction between L1 and Ankyrins
  • Cell-cell junction organization
  • EPH-ephrin mediated repulsion of cells
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
  • Gap junction trafficking and regulation
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Folding of actin by CCT/TriC
  • Innate Immune System
  • Cell junction organization
  • Protein folding
  • Formation of annular gap junctions
  • Chromatin organization
  • Gap junction trafficking
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • Signaling by VEGF
  • Chaperonin-mediated protein folding
  • Cell-extracellular matrix interactions
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
ACTL6A and MYC actin-like 6A v-myc avian myelocytomatosis viral oncogene homolog
  • Chromatin modifying enzymes
  • Chromatin organization
  • HATs acetylate histones
  • RMTs methylate histone arginines
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
ACTN1 and APC actinin, alpha 1 adenomatous polyposis coli
  • Cell junction organization
  • Syndecan interactions
  • Response to elevated platelet cytosolic Ca2+
  • Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
  • Nephrin interactions
  • Platelet degranulation
  • Non-integrin membrane-ECM interactions
  • Platelet activation, signaling and aggregation
  • Cell-extracellular matrix interactions
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Programmed Cell Death
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Apoptotic cleavage of cellular proteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Apoptotic execution phase
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
ACVR1 and TGFBR2 activin A receptor, type I transforming growth factor, beta receptor II (70/80kDa)
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adenosine triphosphate
  • 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
  • Glycerol
ACVRL1 and TGFBR2 activin A receptor type II-like 1 transforming growth factor, beta receptor II (70/80kDa)
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adenosine triphosphate
  • Glycerol
ADH6 and KRAS alcohol dehydrogenase 6 (class V) Kirsten rat sarcoma viral oncogene homolog
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • Ethanol oxidation
  • Metabolic disorders of biological oxidation enzymes
  • Defective CYP1B1 causes Glaucoma
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • Phase 1 - Functionalization of compounds
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Biological oxidations
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Signalling to RAS
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Adaptive Immune System
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • Activation of RAS in B cells
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Constitutive Signaling by EGFRvIII
PARP1 and RNF146 poly (ADP-ribose) polymerase 1 ring finger protein 146
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • degradation of AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • Carba-Nicotinamide-Adenine-Dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
  • trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
ADRBK1 and EGF adrenergic, beta, receptor kinase 1 epidermal growth factor
  • G alpha (q) signalling events
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • CaM pathway
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Hedgehog 'on' state
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Calmodulin induced events
  • Signalling by NGF
  • DAP12 interactions
  • PLC beta mediated events
  • Opioid Signalling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Calmodulin induced events
  • Downstream signal transduction
  • PLC-gamma1 signalling
  • Signaling by Hedgehog
  • Signaling by EGFR in Cancer
  • Activation of SMO
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • GRB2 events in ERBB2 signaling
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Response to elevated platelet cytosolic Ca2+
  • Innate Immune System
  • Signaling by PDGF
  • EGFR downregulation
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Constitutive Signaling by EGFRvIII
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Adenosine triphosphate
  • Sucralfate
  • Alpha-Aminobutyric Acid
ADRBK1 and MDM2 adrenergic, beta, receptor kinase 1 MDM2 proto-oncogene, E3 ubiquitin protein ligase
  • G alpha (q) signalling events
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • CaM pathway
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Hedgehog 'on' state
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Calmodulin induced events
  • Signalling by NGF
  • DAP12 interactions
  • PLC beta mediated events
  • Opioid Signalling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Calmodulin induced events
  • Downstream signal transduction
  • PLC-gamma1 signalling
  • Signaling by Hedgehog
  • Signaling by EGFR in Cancer
  • Activation of SMO
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Stabilization of p53
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • PIP3 activates AKT signaling
  • Oncogene Induced Senescence
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Signalling by NGF
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Trafficking of AMPA receptors
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • Oxidative Stress Induced Senescence
  • Cell Cycle Checkpoints
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • Adenosine triphosphate
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
ADRBK1 and EGFR adrenergic, beta, receptor kinase 1 epidermal growth factor receptor
  • G alpha (q) signalling events
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • CaM pathway
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Hedgehog 'on' state
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Calmodulin induced events
  • Signalling by NGF
  • DAP12 interactions
  • PLC beta mediated events
  • Opioid Signalling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Calmodulin induced events
  • Downstream signal transduction
  • PLC-gamma1 signalling
  • Signaling by Hedgehog
  • Signaling by EGFR in Cancer
  • Activation of SMO
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Adenosine triphosphate
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
AP2A1 and SHC1 adaptor-related protein complex 2, alpha 1 subunit SHC (Src homology 2 domain containing) transforming protein 1
  • Trafficking of GluR2-containing AMPA receptors
  • Retrograde neurotrophin signalling
  • Axon guidance
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Host Interactions of HIV factors
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Trafficking of AMPA receptors
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
  • PCP/CE pathway
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Signaling by GPCR
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • SHC1 events in ERBB2 signaling
  • IRE1alpha activates chaperones
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • SHC-mediated signalling
  • G-protein beta:gamma signalling
  • SHC-related events triggered by IGF1R
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • GPCR downstream signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Signalling to ERKs
  • IGF1R signaling cascade
  • XBP1(S) activates chaperone genes
  • G beta:gamma signalling through PI3Kgamma
  • Unfolded Protein Response (UPR)
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SHC-mediated signalling
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • SHC1 events in EGFR signaling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by EGFRvIII
  • SHC activation
AP2A2 and SHC1 adaptor-related protein complex 2, alpha 2 subunit SHC (Src homology 2 domain containing) transforming protein 1
  • Retrograde neurotrophin signalling
  • Axon guidance
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • Signaling by GPCR
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • SHC1 events in ERBB2 signaling
  • IRE1alpha activates chaperones
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • SHC-mediated signalling
  • G-protein beta:gamma signalling
  • SHC-related events triggered by IGF1R
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • GPCR downstream signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Signalling to ERKs
  • IGF1R signaling cascade
  • XBP1(S) activates chaperone genes
  • G beta:gamma signalling through PI3Kgamma
  • Unfolded Protein Response (UPR)
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SHC-mediated signalling
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • SHC1 events in EGFR signaling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by EGFRvIII
  • SHC activation
AP2B1 and APC adaptor-related protein complex 2, beta 1 subunit adenomatous polyposis coli
  • Retrograde neurotrophin signalling
  • Axon guidance
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • misspliced GSK3beta mutants stabilize beta-catenin
  • APC truncation mutants have impaired AXIN binding
  • T41 mutants of beta-catenin aren't phosphorylated
  • truncated APC mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • RNF mutants show enhanced WNT signaling and proliferation
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Programmed Cell Death
  • Beta-catenin phosphorylation cascade
  • truncations of AMER1 destabilize the destruction complex
  • Apoptotic cleavage of cellular proteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Apoptotic execution phase
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • deletions in the AMER1 gene destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
AP2B1 and SMAD4 adaptor-related protein complex 2, beta 1 subunit SMAD family member 4
  • Retrograde neurotrophin signalling
  • Axon guidance
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by BMP
  • Transcriptional regulation of pluripotent stem cells
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer

Page 9 out of 1171 pages